.webp)
Lyophilization, also known as freeze-drying, is a critical technology for improving the stability and shelf life of drug products, including biologics and other complex modalities. Many drug substances that demonstrate strong biological activity struggle to remain stable in solution long enough to meet the 24-month shelf life typically required for commercial viability. Lyophilization addresses this challenge by converting liquid formulations into dry, solid products that can be stored and transported under refrigerated conditions rather than frozen, reducing logistical complexity.
Jan 14, 2026
.webp)
Flow chemistry scale-up has become an increasingly important focus in modern drug development programs. Compared to traditional batch processing, flow chemistry offers advantages in speed, safety, process control, and sustainability. Although these benefits are well-documented, many organizations struggle to fully realize them. The challenge is often not adopting flow chemistry in the lab but scaling the process efficiently as molecules move toward clinical and commercial manufacturing.
Jan 13, 2026
.webp)
The pharmaceutical industry relies on dependable API manufacturing services to ensure that drug products reach patients safely and on time. Disruptions in the supply chain – whether from natural disasters, regulatory issues, or global crises – can delay production and impact patient care. Many companies address these risks by partnering with CDMOs that implement business continuity management (BCM) strategies to ensure supply from development through commercialization.
Jan 12, 2026
.png)
In vitro biology plays a pivotal role in modern research, providing a controlled environment for studying cellular, molecular, and developmental processes outside living organisms. From drug discovery & preclinical testing to plant studies in in vitro cellular & developmental biology, this approach allows scientists to generate reliable, reproducible data while minimizing reliance on animal models.
Jan 09, 2026
.webp)
Bioconjugates are hybrid molecules that combine a biologic, such as an antibody, with a small molecule payload to create targeted therapies. These constructs, including antibody-drug conjugates (ADCs), leverage the specificity of biologics and the potency of small molecules, enabling more precise treatment of complex diseases like cancer. Developing these molecules requires advanced bioconjugate chemistry and expertise in both biologic and small molecule drug development.
Jan 05, 2026
.webp)
.webp)
.webp)
.png)
.webp)
.png)
.png)
.png)
.webp)
.png)
.png)
.webp)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
-1.png)
-1.png)
-1.png)
.png)
.png)
.png)
.png)
-1.png)
.png)
.png)
.png)
